Changing How We Treat Relapsed/Refractory Hairy Cell Leukemia

Most patients with hairy cell leukemia (HCL) will eventually relapse following first-line purine analogue therapy, and some will develop purine analogue–refractory disease. Targeted therapies have improved outcomes for these patients with difficult-to-treat disease. Take this opportunity to deepen your understanding of current and evolving best practices for the treatment of patients with relapsed/refractory HCL.
Farhad Ravandi, MD

Module

Farhad Ravandi, MD, examines evolving new approaches to hairy cell leukemia, including the antibody-drug conjugate moxetumomab pasudotox, BRAF inhibitors, and combination regimens.

Farhad Ravandi, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 24, 2019 Expiration: April 23, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?